Belatacept in Kidney Transplantation: A Single-center Experience

IF 0.8 4区医学 Q4 IMMUNOLOGY

Transplantation proceedings Pub Date : 2025-01-01 DOI:10.1016/j.transproceed.2024.12.007

Maria Fernandez Martin , Oihane Abaunza de Juan , Monica Paola Rodriguez Davis , Nerea Ormaetxe Ruiz de Hilla , Neike Murua Etxarri , Raquel Vila I Noguer , Isabel Benito Castaño , Eva Maria Alvarez Quintana , Iñigo Yañez Mendia , Sofia Zarraga Larrondo

{"title":"Belatacept in Kidney Transplantation: A Single-center Experience","authors":"Maria Fernandez Martin , Oihane Abaunza de Juan , Monica Paola Rodriguez Davis , Nerea Ormaetxe Ruiz de Hilla , Neike Murua Etxarri , Raquel Vila I Noguer , Isabel Benito Castaño , Eva Maria Alvarez Quintana , Iñigo Yañez Mendia , Sofia Zarraga Larrondo","doi":"10.1016/j.transproceed.2024.12.007","DOIUrl":null,"url":null,"abstract":"<div><div>Belatacept was introduced as an immunosuppressant for kidney transplantation in 2010, but its use in Spain remains limited. Since its commercialization, 15 kidney transplant recipients have received immunosuppressive treatment with belatacept at the Cruces University Hospital. This observational and retrospective study analyzes the reasons for switching to belatacept, its impact on kidney function, and the drug's safety profile. In all cases, it was used as a maintenance immunosuppressant rather than for induction, and its use was determined by the presence of severe side effects from other immunosuppressants, particularly calcineurin inhibitors. The estimated glomerular filtration rate during the first year increased in patients who had previously experienced nephrotoxicity from calcineurin inhibitors and remained stable in the others, whereas proteinuria improved in patients who had been treated with mammalian target of rapamycin inhibitors. Additionally, no adverse effects clearly related to belatacept were observed. This analysis suggests that belatacept is a safe and well-tolerated drug that does not negatively affect kidney function and may even have a beneficial effect on certain groups of patients. Therefore, it presents a therapeutic alternative to consider in patients with serious contraindications to other treatments.</div></div>","PeriodicalId":23246,"journal":{"name":"Transplantation proceedings","volume":"57 1","pages":"Pages 7-9"},"PeriodicalIF":0.8000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transplantation proceedings","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0041134524006584","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Belatacept was introduced as an immunosuppressant for kidney transplantation in 2010, but its use in Spain remains limited. Since its commercialization, 15 kidney transplant recipients have received immunosuppressive treatment with belatacept at the Cruces University Hospital. This observational and retrospective study analyzes the reasons for switching to belatacept, its impact on kidney function, and the drug's safety profile. In all cases, it was used as a maintenance immunosuppressant rather than for induction, and its use was determined by the presence of severe side effects from other immunosuppressants, particularly calcineurin inhibitors. The estimated glomerular filtration rate during the first year increased in patients who had previously experienced nephrotoxicity from calcineurin inhibitors and remained stable in the others, whereas proteinuria improved in patients who had been treated with mammalian target of rapamycin inhibitors. Additionally, no adverse effects clearly related to belatacept were observed. This analysis suggests that belatacept is a safe and well-tolerated drug that does not negatively affect kidney function and may even have a beneficial effect on certain groups of patients. Therefore, it presents a therapeutic alternative to consider in patients with serious contraindications to other treatments.

查看原文本刊更多论文

Belatacept在肾移植中的应用：单中心经验。

2010年，Belatacept作为一种免疫抑制剂被引入肾移植，但它在西班牙的使用仍然有限。自其商业化以来，15名肾移植受者在克鲁塞斯大学医院接受了belatacept的免疫抑制治疗。这项观察性和回顾性研究分析了切换到belataccept的原因，其对肾功能的影响，以及药物的安全性。在所有病例中，它被用作维持免疫抑制剂，而不是用于诱导，其使用是由其他免疫抑制剂，特别是钙调磷酸酶抑制剂的严重副作用决定的。在先前因钙调磷酸酶抑制剂而出现肾毒性的患者中，第一年肾小球滤过率估计增加，而在其他患者中保持稳定，而在接受雷帕霉素抑制剂的哺乳动物靶点治疗的患者中，蛋白尿有所改善。此外，未观察到与迟拉西普明显相关的不良反应。这一分析表明，belatacept是一种安全且耐受性良好的药物，不会对肾功能产生负面影响，甚至可能对某些患者群体产生有益影响。因此，对于其他治疗有严重禁忌症的患者，它是一种可考虑的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Transplantation proceedings 医学-免疫学

CiteScore

1.70

自引率

0.00%

发文量

502

审稿时长

60 days

期刊介绍： Transplantation Proceedings publishes several different categories of manuscripts, all of which undergo extensive peer review by recognized authorities in the field prior to their acceptance for publication. The first type of manuscripts consists of sets of papers providing an in-depth expression of the current state of the art in various rapidly developing components of world transplantation biology and medicine. These manuscripts emanate from congresses of the affiliated transplantation societies, from Symposia sponsored by the Societies, as well as special Conferences and Workshops covering related topics. Transplantation Proceedings also publishes several special sections including publication of Clinical Transplantation Proceedings, being rapid original contributions of preclinical and clinical experiences. These manuscripts undergo review by members of the Editorial Board. Original basic or clinical science articles, clinical trials and case studies can be submitted to the journal?s open access companion title Transplantation Reports.